The EPS projection of Seattle Genetics, Inc. (NASDAQ:SGEN) for quarter ended 2016-09-30 is $-0.32. Last week, the projection for EPS was $-0.32 against target of $-0.32, a month earlier. While 2-months ago, this projection was $-0.32 versus forecast of $-0.32a quarter months earlier, posting a deviation of 0%.
Seattle Genetics, Inc. (NASDAQ:SGEN) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 2.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for Seattle Genetics, Inc. (NASDAQ:SGEN) in the preceding 30 and 120 were 0 and 5. While in 60 and 90 days were 0, and 5, in that order.
Seattle Genetics, Inc. (NASDAQ:SGEN) EPS target was $-0.32 for the quarter closed 1. It was based on 9 calls. As on 2016-04-28 the EPS was $-0.15. The change was $-0.04, posting a deviation of -36.36%. The price projections gave a standard deviation of 0.05.
Quarterly Sales Estimates
Seattle Genetics, Inc. (NASDAQ:SGEN) sales prediction for the fiscal 2016 stands at $109.352 and the median estimate is at $107.85. Almost 5 analysts gave sales target.
Among this, the highest sales estimate is $117.563 while the lowest target is $104.3 showing standard deviation of 5.17%.
As many as 5 analysts have positive sales targets revision while 5 reduced sales estimates, posting a deviation of 0%.
Last month, 5 experts have positive sales number revision. Also, 5 research groups lowered the sales projections, posting a deviation of -0.073%.
A quarter ago, 5 hiked sales target and 5 reduced sales forecast, posting a deviation of 1.817%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...